Gut brain axis: an insight into microbiota role in Parkinson’s disease

Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P, Scheperjans F (2019) Gut microbiota in Parkinson’s disease: temporal stability and relations to disease progression. EBioMedicine 44:691–707 Alecu I, Bennett SAL (2019) 'Dysregulated lipid metabolism and its role in α-synucleinopathy in Parkinson’s disease. Front Neurosci 13(328) Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol 15(12):1257–1272. https://doi.org/10.1016/S1474-4422(16)30230-7 Baizabal-Carvallo J (2021) Gut microbiota: a potential therapeutic target for Parkinsons disease. Neural Regen Res 16(2):287. https://doi.org/10.4103/1673-5374.290896 Barry TJ, Murray L, Fearon P, Moutsiana C, Johnstone T, Halligan SL (2017) Amygdala volume and hypothalamic-pituitary-adrenal axis reactivity to social stress. Psychoneuroendocrinology 85:96–99 Beitz JM (2014) Parkinson’s disease: a review. Front Biosci (schol Ed) 6:65–74 Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP (2016) Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. Parkinsonism Relat Disord 23:1–9 Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211 Britannica TE (2018) Digestive nerve plexus Butterworth AD, Thomas AG, Akobeng AK (2008) Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008(3):CD006634-CD006634 Cammarota G, Pecere S, Ianiro G, Masucci L, Currò D (2016) Principles of DNA-based gut microbiota assessment and therapeutic efficacy of fecal microbiota transplantation in gastrointestinal diseases. Dig Dis 34(3):279–285 Cassani E, Privitera G, Pezzoli G, Pusani C, Madio C, Iorio L, Barichella M (2011) Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol Dietol 57(2):117–121 Chen Z-J, Liang C-Y, Yang L-Q, Ren S-M, Xia Y-M, Cui L et al (2021) Association of Parkinson’s disease with microbes and microbiological therapy. Front Cell Infect Microbiol. https://doi.org/10.3389/fcimb.2021.619354 Cirstea MS, Yu AC, Golz E, Sundvick K, Kliger D, Radisavljevic N, Foulger LH, Mackenzie M, Huan T, Finlay BB, Appel-Cresswell S (2020) Microbiota composition and metabolism are associated with gut function in Parkinson’s disease. Mov Disord 35(7):1208–1217 Costa M, Brookes SJ, Hennig GW (2000) Anatomy and physiology of the enteric nervous system. Gut 47 (Suppl 4):iv15–iv26 Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13(10):701–712. https://doi.org/10.1038/nrn3346 Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi SJ, Berenjian A, Ghasemi Y (2019) Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods 8(3):92 Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, Letley D, Harbin L, Price AB, Ibrahim MA, Oxlade NL, Bowthorpe J, Leckstroem D, Smee C, Plant JM, Peterson DW (2010) Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism. Helicobacter 15(4):279–294 Doroftei B, Ilie OD, Cojocariu RO, Ciobica A, Maftei R, Grab D, Anton E, McKenna J, Dhunna N, Simionescu G (2020) Minireview exploring the biological cycle of vitamin B3 and its influence on oxidative stress: further molecular and clinical aspects. Molecules 25(15) Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR et al (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinsons disease. Proc Natl Acad Sci 98(25):14669–14674. https://doi.org/10.1073/pnas.251341998 Dutta SK, Verma S, Jain V, Surapaneni BK, Vinayek R, Phillips L, Nair PP (2019) Parkinson’s disease: the emerging role of gut dysbiosis, antibiotics, probiotics, and fecal microbiota transplantation. J Neurogastroenterol Motil 25(3):363–376 Elfil M, Kamel S, Kandil M, Koo BB, Schaefer SM (2020) Implications of the gut microbiome in Parkinson’s disease. Mov Disord 35(6):921–933 Fang X (2019) Microbial treatment: the potential application for Parkinson’s disease. Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol 40(1):51–58 Fanning S, Selkoe D, Dettmer U (2020) Parkinson’s disease: proteinopathy or lipidopathy? NPJ Parkinsons Dis 6:3 Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, Barbaro F, Piano C, Fortuna S, Tortora A, Di Giacopo R, Campanale M, Gigante G, Lauritano EC, Navarra P, Marconi S, Gasbarrini A, Bentivoglio AR (2013) The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 28(9):1241–1249 Fields CT, Sampson TR, Bruce-Keller AJ, Kiraly DD, Hsiao EY, de Vries GJ (2018) Defining dysbiosis in disorders of movement and motivation. J Neurosci 38(44):9414 Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A (2011) Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PloS ONE 6(12):e28032 Furness JB, Callaghan BP, Rivera LR, Cho HJ (2014) The enteric nervous system and gastrointestinal innervation: integrated local and central control. Adv Exp Med Biol 817:39–71 Gazerani P (2019) Probiotics for Parkinson’s disease. Int J Mol Sci 20(17):4121 Georgescu D, Ancusa OE, Georgescu LA, Ionita I, Reisz D (2016) Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: is there hope? Clin Interv Aging 11:1601–1608 Getz SJ, Levin B (2017) Cognitive and neuropsychiatric features of early Parkinson’s disease. Arch Clin Neuropsychol 32(7):769–785 Goedert M, Masuda-Suzukake M, Falcon B (2017) Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain 140(2):266–278 González-Lizárraga F, Socías SB, Ávila CL, Torres-Bugeau CM, Barbosa LR, Binolfi A, Sepúlveda-Díaz JE, Del-Bel E, Fernandez CO, Papy-Garcia D, Itri R, Raisman-Vozari R, Chehín RN (2017) Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species. Sci Rep 7:41755. https://doi.org/10.1038/srep41755 Graham SF, Rey NL, Ugur Z, Yilmaz A, Sherman E, Maddens M, Bahado-Singh RO, Becker K, Schulz E, Meyerdirk LK, Steiner JA, Ma J, Brundin P (2018) Metabolomic profiling of bile acids in an experimental model of prodromal parkinson’s disease. Metabolites 8(4):71 Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K, Shibata A, Fujisawa Y, Minato T, Okamoto A, Ohno K, Hirayama M (2015) Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in parkinson’s disease. PLOS ONE 10(11):e0142164 Hasuike Y, Endo T, Koroyasu M, Matsui M, Mori C, Yamadera M, Fujimura H, Sakoda S (2020) Bile acid abnormality induced by intestinal dysbiosis might explain lipid metabolism in Parkinson's disease. Med Hypotheses 134:109436 Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B, Wilmes P (2018) The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord 33(1):88–98 Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R, Payami H (2017) Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov Disord 32(5):739–749 Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME (2014) The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11(8):506–514 Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, Carroll C (2014) Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathol 127(2):235–241 Hopfner F, Künstner A, Müller SH, Künzel S, Zeuner KE, Margraf NG, Deuschl G, Baines JF, Kuhlenbäumer G (2017) Gut microbiota in Parkinson disease in a northern German cohort. Brain Res 1667:41–45 Hsieh TH, Kuo CW, Hsieh KH, Shieh MJ, Peng CW, Chen YC, Chang YL, Huang YZ, Chen CC, Chang PK, Chen KY, Chen HY (2020) Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson's disease. Brain Sci 10(4) Huang H, Xu H, Luo Q, He J, Li M, Chen H, Tang W, Nie Y, Zhou Y (2019) Fecal microbiota transplantation to treat Parkinson’s disease with constipation: a case report. Medicine 98(26):e16163–e16163 Hwang O (2013) Role of oxidative stress in Parkinson’s disease. Exp Neurobiol 22(1):11–17 Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM (2015) Colonic bacterial composition in Parkinson’s disease. Mov Disord 30(10):1351–1360 Kilzheimer A, Hentrich T, Burkhardt S, Schulze-Hentrich JM (2019) The challenge and opportunity to diagnose Parkinson's disease in midlife. Front Neurol, 10(1328) Kleinman M, Frank S (2013) Epidemiology and clinical diagnosis of Parkinson disease. PET Clin 8(4):447–458 Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F (2016) From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165(6):1332–1345 Konturek PC, Koziel J, Dieterich W, Haziri D, Wirtz S, Glowczyk I, Konturek K, Neurath MF, Zopf Y (2016) Successful therapy of Clostridium difficile infection with fecal microbiota transplantation. J Physiol Pharmacol 67(6):859–866 Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E (2017) Dysbiosis and the immune system. Nat Rev Immunol 17(4):219–232 Liang S, Wang T, Hu X, Luo J, Li W, Wu X, Duan Y, Jin F (2015) Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience 310:561–577 Long-Smith C, O’Riordan KJ, Clarke G, Stanton C, Dinan TG, Cryan JF (2020) Microbiota-gut-brain axis: new therapeutic opportunities. Annu Rev Pharmacol Toxicol 60:477–502 Lopetuso LR, Napoli M, Rizzatti G, Scaldaferri F, Franceschi F, Gasbarrini A (2018) Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Exp Rev Gastroenterol Hepatol 12(9):899–906 Lorente-Picón M, Laguna A (2021) New avenues for Parkinson’s disease therapeutics: disease-modifying strategies based on the gut microbiota. Biomolecules 11(3):433. https://doi.org/10.3390/biom11030433 Lubomski M, Tan AH, Lim SY, Holmes AJ, Davis RL, Sue CM (2020) Parkinson’s disease and the gastrointestinal microbiome. J Neurol 267(9):2507–2523 Maes M, Kubera M, Leunis JC (2008) The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 29(1):117–124 Magistrelli L, Amoruso A, Mogna L, Graziano T, Cantello R, Pane M, Comi C (2019) Probiotics may have beneficial effects in parkinson’s disease: in vitro evidence. Front Immunol 10:969–969 McGee DJ, Lu XH, Disbrow EA (2018) Stomaching the possibility of a pathogenic role for helicobacter pylori in parkinson’s Disease. J Parkinsons Dis 8(3):367–374 Miraglia F, Colla E (2019) Microbiome, Parkinson's disease and molecular mimicry. Cells 8(3) Mulak A, Bonaz B (2015) Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol 21(37):10609–10620 Myers K (2019) Gut/brain axis and its role in Parkinson’s disease progression. unpublished thesis (Creative Components), Iowa State University Nag N, Jelinek GA (2019) A narrative review of lifestyle factors associated with Parkinson’s disease risk and progression. Neurodegener Dis 19(2):51–59 O’Donovan SM, Crowley EK, Brown JR, O’Sullivan O, O’Leary OF, Timmons S, Nolan YM, Clarke DJ, Hyland NP, Joyce SA, Sullivan AM, O’Neill C (2020) Nigral overexpression of α-synuclein in a rat Parkinson’s disease model indicates alterations in the enteric nervous system and the gut microbiome. Neurogastroenterol Motil 32(1):e13726 Ojetti V, Bruno G, Ainora ME, Gigante G, Rizzo G, Roccarina D, Gasbarrini A (2012) Impact of Lactobacillus reuteri supplementation on anti-helicobacter pylori levofloxacin-based second-line therapy. Gastroenterol Res Pract 740381 Oligschlaeger Y, Yadati T, Houben T, Oliván CMC, Shiri-Sverdlov R (2019) Inflammatory bowel disease: a stressed, “gut/feeling.” Cells 8(7):659. https://doi.org/10.3390/cells8070659 Pandey KR, Naik SR, Vakil BV (2015) Probiotics, prebiotics and synbiotics—a review. J Food Sci Technol 52(12):7577–7587. https://doi.org/10.1007/s13197-015-1921-1 Parashar A, Udayabanu M (2017) Gut microbiota: implications in Parkinson’s disease. Parkinsonism Relat Disord 38:1–7 Peelaerts W, Baekelandt V (2016) ɑ-Synuclein strains and the variable pathologies of synucleinopathies. J Neurochem 139(Suppl 1):256–274 Perez-Pardo P, Kliest T, Dodiya HB, Broersen LM, Garssen J, Keshavarzian A, Kraneveld AD (2017) The gut-brain axis in Parkinson’s disease: possibilities for food-based therapies. Eur J Pharmacol 817:86–95 Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, Tyakht AV, Kovarsky BA, Alekseev DG, Kostryukova ES, Mironova YS, Izhboldina OP, Nikitina MA, Perevozchikova TV, Fait EA, Babenko VV, Vakhitova MT, Govorun VM, Sazonov AE (2017) Analysis of gut microbiota in patients with Parkinson’s disease. Bull Exp Biol Med 162(6):734–737 Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Frasca S, Galante A, Marciani MG, Stanzione P (2001) Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson’s disease patients. Neurol Sci 22(1):89–91 Pietrucci D, Cerroni R, Unida V, Farcomeni A, Pierantozzi M, Mercuri NB, Biocca S, Stefani A, Desideri A (2019) Dysbiosis of gut microbiota in a selected population of Parkinson’s patients. Parkinsonism Relat Disord 65:124–130 Pietrucci D, Teofani A, Unida V, Cerroni R, Biocca S, Stefani A, Desideri A (2020) Can gut microbiota be a good predictor for Parkinson’s disease? A machine learning approach. Brain Sci 10(4):242 Pinter B, Diem-Zangerl A, Wenning GK, Scherfler C, Oberaigner W, Seppi K, Poewe W (2015) Mortality in Parkinson’s disease: a 38-year follow-up study. Mov Disord 30(2):266–269 Rahne KE, Tagesson C, Nyholm D (2013) Motor fluctuations and Helicobacter pylori in Parkinson’s disease. J Neurol 260(12):2974–2980 Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167(6):1469-1480.e12 Scheperjans F (2016) Gut microbiota, 1013 new pieces in the Parkinson’s disease puzzle. Curr Opin Neurol 29(6):773–780 Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P (2015) Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord 30(3):350–358 Schulz C, Schütte K, Koch N, Vilchez-Vargas R, Wos-Oxley ML, Oxley APA, Vital M, Malfertheiner P, Pieper DH (2018) The active bacterial assemblages of the upper GI tract in individuals with and without <em>Helicobacter</em> infection. Gut 67(2):216 Sender R, Fuchs S, Milo R (2016) Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164(3):337–340 Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH (2012) Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Mov Disord 27(6):716–719 Silva YP, Bernardi A, Frozza RL (2020) The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol 11(25) Slikker W, Paule, Merle G,Wang C (2018) Handbook of developmental neurotoxicology, Second Edition ed. Academic Press. Smith K, McCoy KD, Macpherson AJ (2007) Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol 19(2):59–69 Stephens MAC, Mccaul ME, Wand GS (2014) The potential role of glucocorticoids and the HPA axis in alcohol dependence. Neurobiol Alcohol Dependence. https://doi.org/10.1016/b978-0-12-405941-2.00021-3 Stoilova T, Colombo L, Forloni G, Tagliavini F, Salmona M (2013) A new face for old antibiotics: tetracyclines in treatment of amyloidoses. J Med Chem 56(15):5987–6006. https://doi.org/10.1021/jm400161p Steiner JA, Quansah E, Brundin P (2018) The concept of alpha-synuclein as a prion-like protein: ten years after. Cell Tissue Res 373(1):161–173 Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P (2016) Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol 79(6):940–949 Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, Cui C, Shen YQ (2018) Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun 70:48–60 Sun Y, Zhang M, Chen C-C, Gillilland M, Sun X, El-Zaatari M, Huffnagle GB, Young VB, Zhang J, Hong S-C, Chang Y-M, Gumucio DL, Owyang C, Kao JY (2013) Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 144(7):1478–87, 1487.e1–8 Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sørensen HT (2015) Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol 78(4):522–529 Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, Oryan S, Mafi A, Asemi Z (2019) Clinical and metabolic response to probiotic administration in people with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr 38(3):1031–1035 Ternák G, Kuti D, Kovács KJ (2020) Dysbiosis in Parkinson’s disease might be triggered by certain antibiotics. Med Hypotheses 137:109564 Tysnes OB, Storstein A (2017) Epidemiology of Parkinson’s disease. J Neural Transm (vienna) 124(8):901–905 Ugalde CL, Lawson VA, Finkelstein DI, Hill AF (2019) The role of lipids in α-synuclein misfolding and neurotoxicity. J Biol Chem 294(23):9016–9028 Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, Faßbender K, Schwiertz A, Schäfer KH (2016) Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord 32:66–72 Yang D, Zhao D, Ali Shah SZ, Wu W, Lai M, Zhang X, Li J, Guan Z, Zhao H, Li W, Gao H, Zhou X, Yang L (2019) The role of the gut microbiota in the Pathogenesis of Parkinson’s disease. Front Neurol 10:1155–1155 Zheng D, Liwinski T, Elinav E (2020) Interaction between microbiota and immunity in health and disease. Cell Res 30(6):492–506